HBM Holdings (2142) Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2142 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
HBM Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$15.33 |
| 52 Week High | HK$17.98 |
| 52 Week Low | HK$1.12 |
| Beta | 1.86 |
| 1 Month Change | -4.13% |
| 3 Month Change | 82.72% |
| 1 Year Change | 922.00% |
| 3 Year Change | 706.84% |
| 5 Year Change | n/a |
| Change since IPO | 39.11% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To HBM Holdings Limited (HKG:2142) With Shares Advancing 54%
Aug 16
What HBM Holdings Limited's (HKG:2142) 51% Share Price Gain Is Not Telling You
May 07HBM Holdings' (HKG:2142) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 29HBM Holdings Limited (HKG:2142) Stock Catapults 78% Though Its Price And Business Still Lag The Industry
Feb 20HBM Holdings Limited (HKG:2142) Stock Catapults 58% Though Its Price And Business Still Lag The Industry
Jan 01Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump
Oct 02Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet
Jul 18HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly
May 23Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper
Apr 12HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Jan 01We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate
Feb 08Shareholder Returns
| 2142 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 9.4% | 7.2% | 2.9% |
| 1Y | 922.0% | 116.2% | 20.7% |
Return vs Industry: 2142 exceeded the Hong Kong Biotechs industry which returned 116.2% over the past year.
Return vs Market: 2142 exceeded the Hong Kong Market which returned 20.7% over the past year.
Price Volatility
| 2142 volatility | |
|---|---|
| 2142 Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.8% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 2142 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2142's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 210 | Jingsong Wang | www.harbourbiomed.com |
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm.
HBM Holdings Limited Fundamentals Summary
| 2142 fundamental statistics | |
|---|---|
| Market cap | HK$12.86b |
| Earnings (TTM) | HK$568.55m |
| Revenue (TTM) | HK$900.33m |
Is 2142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2142 income statement (TTM) | |
|---|---|
| Revenue | US$115.71m |
| Cost of Revenue | US$8.16m |
| Gross Profit | US$107.56m |
| Other Expenses | US$34.49m |
| Earnings | US$73.07m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.087 |
| Gross Margin | 92.95% |
| Net Profit Margin | 63.15% |
| Debt/Equity Ratio | 21.7% |
How did 2142 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 18:38 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HBM Holdings Limited is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |
| Tony Ren | CLSA |